# Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930

> **NCT05207761** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 32 (actual)

## Conditions studied

- Glaucoma

## Interventions

- **DRUG:** D565
- **DRUG:** D930

## Key facts

- **NCT ID:** NCT05207761
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-19
- **Primary completion:** 2022-10-18
- **Final completion:** 2022-11-02
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05207761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05207761, "Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05207761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*